Inactive Instrument

Aurinia Pharmaceuticals Inc. Stock price Toronto S.E.

Equities

AUP

CA05156V1022

Biotechnology & Medical Research

Sales 2024 * 223M 302M Sales 2025 * 288M 389M Capitalization 723M 979M
Net income 2024 * -6M -8.12M Net income 2025 * 58M 78.54M EV / Sales 2024 * 1.7 x
Net cash position 2024 * 344M 466M Net cash position 2025 * 390M 529M EV / Sales 2025 * 1.16 x
P/E ratio 2024 *
-90.9 x
P/E ratio 2025 *
12.7 x
Employees 300
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.55%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Founder 52 93-06-15
Chief Executive Officer 54 19-04-28
Founder 65 93-06-15
Members of the board TitleAgeSince
Founder 65 93-06-15
Director/Board Member 73 19-06-25
Chief Executive Officer 54 19-04-28
More insiders
Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory activities to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil (MMF) and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. Its product pipeline includes AUR200 and AUR300.
Related indices
More about the company
  1. Stock
  2. Equities
  3. Stock Aurinia Pharmaceuticals Inc.
  4. Stock Aurinia Pharmaceuticals Inc. - Toronto S.E.